Autor según el artículo: Ettcheto M, Sánchez-López E, Pons L, Busquets O, Olloquequi J, Beas-Zarate C, Pallas M, García ML, Auladell C, Folch J, Camins A.
Departamento: Bioquímica i Biotecnologia
Autor/es de la URV: Folch Lopez, Jaume
Palabras clave: Tau Mitochondria Memory impairment Insulin receptor Hippocampus Dexibuprofen Atiinflamatory drug Appswe/ps1de9 Alzheimer's disease mitochondria memory impairment insulin receptor hippocampus dexibuprofen appswe/ps1de9 alzheimer's disease
Resumen: The aim of the present study is to elucidate the neuronal pathways associated to NSAIDs causing a reduction of the risk and progression of Alzheimer's disease. The research was developed administering the active enantiomer of ibuprofen, dexibuprofen (DXI), in order to reduce associated gastric toxicity. DXI was administered from three to six-month-old female APPswe/PS1dE9 mice as a model of familial Alzheimer's disease. DXI treatment reduced the activation of glial cells and the cytokine release involved in the neurodegenerative process, especially TNFα. Moreover, DXI reduced soluble β-amyloid (Aβ1-42) plaque deposition by decreasing APP, BACE1 and facilitating Aβ degradation by enhancing insulin-degrading enzyme. DXI also decreased TAU hyperphosphorylation inhibiting c-Abl/CABLES/p-CDK5 activation signal pathway and prevented spatial learning and memory impairment in transgenic mice. Therefore, chronic DXI treatment could constitute a potential AD-modifying drug, both restoring cognitive functions and reversing multiple brain neuropathological hallmarks.
Áreas temáticas: Química Organic chemistry Odontología Medicina ii Medicina i Farmacia Clinical biochemistry Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Biotecnología Biodiversidade Biochemistry & molecular biology Biochemistry Astronomia / física
Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
ISSN: 22132317
Direcció de correo del autor: jaume.folch@urv.cat
Identificador del autor: 0000-0002-5051-8858
Fecha de alta del registro: 2024-09-07
Versión del articulo depositado: info:eu-repo/semantics/publishedVersion
Enlace a la fuente original: https://www.sciencedirect.com/science/article/pii/S2213231717302823
URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/
Referencia al articulo segun fuente origial: Redox Biology. 13 345-352
Referencia de l'ítem segons les normes APA: Ettcheto M, Sánchez-López E, Pons L, Busquets O, Olloquequi J, Beas-Zarate C, Pallas M, García ML, Auladell C, Folch J, Camins A. (2017). Dexibuprofen prevents neurodegeneration and cognitive decline in APPswe/PS1dE9 through multiple signaling pathways.. Redox Biology, 13(), 345-352. DOI: 10.1016/j.redox.2017.06.003
DOI del artículo: 10.1016/j.redox.2017.06.003
Entidad: Universitat Rovira i Virgili
Año de publicación de la revista: 2017
Tipo de publicación: Journal Publications